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Objective: The aim of this study was to obtain comprehensive
information on basal hypothalamic–pituitary–adrenal (HPA) axis
activity in chronic fatigue syndrome (CFS) patients who were not
affected by medication or comorbid psychiatric disorder likely to
influence the HPA axis. Method: Steroid analysis of urine
collections from 0600 to 2100 h at 3-h intervals in CFS patients
and in controls. Results: Urinary free cortisol and cortisone
concentrations showed a significant normal diurnal rhythm, but
levels were lower across the cycle in CFS. In contrast, while urinary0022-3999/06/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.jpsychores.2005.07.008
T Corresponding author. Tel.: +44 020 7346 4131; fax: +44 0207 737
7434.
E-mail address: jerjes@kcl.ac.uk (W.K. Jerjes).cortisol metabolites also showed a normal diurnal rhythm, levels
were not significantly different between the CFS and controls at any
time. Derived metabolite ratios were similar in both groups.
Conclusion: This study provides further evidence for reduced basal
HPA axis function in patients with CFS, based on lower free cortisol
and cortisone levels, but this is not corroborated by cortisol
metabolite data. The difference between these measures cannot be
explained by an altered timing of the diurnal rhythm.
D 2006 Elsevier Inc. All rights reserved.Keywords: Chronic fatigue syndrome (CFS); Diurnal rhythm; Metabolism; Urinary cortisol; Urinary cortisoneIntroduction
Chronic fatigue syndrome (CFS) is characterised by
persistent debilitating fatigue and exhaustion, together with
a number of other characteristic symptoms, unexplained by
identifiable organic disease [1]. The aetiology of CFS remains
unclear, although there is evidence that biological, psycho-
logical, and social factors all play a part [2]. Many of thesymptoms of CFS can also be associated with glucocorticoid
deficiency states, and low serum cortisol was reported in early
studies of patients with CFS and other fatigue states [3,4].
These results–from the evening and morning, respectively–
could reflect a general hypocortisolaemia in CFS. However,
other studies have shown no differences in serum cortisol
levels [5,6]. Thus, there remains some inconsistency in
research to date using serum cortisol to measure basal
hypothalamo–pituitary–adrenal (HPA) axis function in CFS.
Assessment of HPA axis function by urine analysis offers
advantages. Samples are obtained by a noninvasive, stress-free
procedure and are easier to collect than blood [7,8]. Urinary
free cortisol is considered to reflect the integrated, unbound
plasma cortisol levels andwas originally used in examining theearch 60 (2006) 145–153
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cortisol levels have generally shown good agreement with
plasma cortisol levels in hypercortisolaemic states [7], and
elevated levels in depression are reduced following treatment,
mirroring clinical improvements [9]. However, observations in
CFS have again reached variable conclusions. Four studies
have found a low basal output of urinary free cortisol over
24 h [3,10–12] and two found no change [13,14]. It is possible
that this variability might be explained by changes in
steroid metabolism, rather than changes in circulating cortisol
levels per se because free cortisol in urine represents only
2–3% of the urinary cortisol metabolites [15].
To overcome the problem outlined above, we first
examined the 24-h urinary excretion of total cortisol
metabolites (TCM) in patients with CFS and found them
to be unchanged in comparison with that of healthy
controls (Jerjes et al., unpublished data). This method,
which is based on gas chromatography, and quantifies
N95% of cortisol production per day, provides a sensitive
means of detecting changes in rates of cortisol secretion, as
has been demonstrated in asthmatics treated with inhaled
glucocorticoids [16]. It also permits examination of
changes in cortisol metabolism such as cortisol–cortisone
interconversion. Cortisol converts reversibly into cortisone
in blood, under the control of the 11-h-hydroxysteroid
dehydrogenase (11-h-HSD Types 1 and 2) enzyme.
Alteration in this equilibrium has been reported in various
diseases [17,18].
The apparent difference of cortisol production in CFS
based on serum point estimation and integrated values in
urine might be explained by changed timing of the diurnal
rhythm. This is supported by observations that CFS-like
symptoms can also be seen in some conditions in which the
circadian clock is phase shifted, such as seasonal affective
disorder and major depression [19–21]. Few studies have
attempted to measure the diurnal or circadian rhythm of
cortisol in CFS. MacHale et al. [22] demonstrated a signifi-
cantly lower diurnal change of serum cortisol in CFS based
on evening and morning sampling over two consecutive
days. Additionally, there was a significant positive relation-
ship between the degree of diurnal variation in cortisol and
measures of functional capacity. In two studies based on 4-h
blood sampling, Hamilos et al. [14] reported a flattened
diurnal rhythm of plasma cortisol in patients with CFS,
whereas Racciatti et al. [5] did not find a significant change
in cortisol rhythm in CFS. We therefore aimed to recruit a
new group of well-characterised CFS patients free from
medication or comorbid psychiatric disorders that might
confound assessment of the HPA axis and measure the
levels of urinary free cortisol, cortisone, and their metabo-
lites across a diurnal cycle to provide further information
regarding the status of the HPA axis in CFS. We
hypothesised that we would find a reduction in free cortisol
output throughout the day, and that this would also be
accompanied by a change in measures of the diurnal rhythm
of cortisol and its metabolites.Materials and methods
Participants
Fifteen patients with CFS (7 males and 8 females) were
recruited via the CFS clinic at King’s College Hospital
(KCH), which sees secondary and tertiary care referrals from
the south of the United Kingdom. Participants were inter-
viewed by experienced psychiatrists who used the semi-
structured interview for CFS of Sharpe et al. [23] and DSM-IV
to determine the presence of any psychiatric diagnoses.
Participants were eligible for inclusion if they fulfilled the
1994 Center for Disease Control (CDC) criteria for CFS [1]
without any exclusionary psychiatric disorder as per these
criteria. Further inclusion criteria stipulated an age range of
25–60 years and the absence of any history of neurological,
endocrine, or cardiovascular disorder. To obtain as pure a
measure of the HPA axis as possible, we tested only patients
who had never taken any psychotropic medication or had been
abstinent from such medication for at least 2 months.
Furthermore, although the modification of the original CDC
diagnostic criteria in 1994 permitted the inclusion of patients
with comorbid major depression or anxiety disorders, patients
with a current major depressive episode or anxiety disorder as
defined by DSM-IV criteria were excluded from this study
because of their potential impact on the HPA axis. Patients
were recruited consecutively over about 6 months. None of
them had taken part in any of our previously published studies.
Twenty healthy volunteers (10males and 10 females) were
recruited among the staff and student body at KCH and were
well matched for age, sex, and BMI with the CFS patients.
They were all in good health, without any serious medical
illness or history of psychiatric disorder. Participants were all
studied during winter, between October 2002 and March
2003. All participants had normal dietary habits, taking
breakfast, lunch, and dinner at about the same time. All
participants habitually went to bed between 2300 and 0100 h
and got up between 0600 and 0800 h. All participants were
asked to limit their intake of caffeine and alcohol during the
collection period. While these agents may have effects on the
HPA axis, it was considered that short-term avoidance of
habitual intake would result in more disturbance of the axis.
All participants were instructed to carry out sample collec-
tions at weekends to avoid possible increase of cortisol levels
that might result from stress on working days. No female
participants were on oral contraceptive or were pregnant. All
participants gave written, informed consent and ethical ap-
proval for the study was obtained from our local committee.
Questionnaires
All participants completed the Hospital Anxiety and
Depression scale (HADS) [24] for symptoms of anxiety
and depression and the Pittsburgh Sleep Quality Index
(PSQI; [25]) for sleep disturbance. Patients completed further
questionnaires to characterise their illness: the Chalder
Table 1





Age (years) 35F7.9 33F11.3 P=.4
BMI 24.4F50 24.2F4.6 P=.6
HADS questionnaire scores
Depression 8.0F3.9 3.0F2.7 Pb.01
Anxiety 7.3F5.6 3.1F2.6 Pb.01
PSQI global scores 9.8F3.3 2.2F1.3 Pb.01
Duration of illness (years) 2.7F0.6 N/A N/A
Scores on the Chalder Fatigue
Questionnaire (maximum=33)
25.1F3.0 N/A N/A
Disability from illness on the
Work and Social Adjustment
Scale (maximum=40)
22.5F4.7 N/A N/A
Data are presented as meanFS.D.
Fig. 1. Mean values and standard errors of (A) urinary cortisol, (B) urinary
cortisone, and (C) urinary cortisol/cortisone ratio in CFS patients (n=15)
and healthy controls (n=20) at a 3-h interval for 15 h. *Pb.05, **Pb.01,
and ***Pb.001.
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Social Adjustment Scale [27] for disability.
Urine collections
Participants were provided with standard containers
without additives for 3-h urine collections and given clear
instructions on how to complete the collection. They were
told to collect urine for five 3-h blocks over the course of a
day, starting at 0600 h, for a total of 15 h. They were
instructed to empty their bladder normally at 0600 h and to
collect all passed urine (if any) into the first container (for
period 0600–0900 h). At 0900 h, they were to empty their
bladder into the container and end that 3-h collection. All
urine thereafter was to go into the 0900–1200 h container,
and the bladder emptied at 1200 h to end that collection, and
so forth, until 2100 h.
Upon receipt of the specimen at the laboratory, the exact
volume was noted, and after vigorous shaking, two 20-ml
aliquots were taken for freezing at 40 8C prior to sub-
sequent analysis.
Urinary free cortisol and cortisone measurements
Urine cortisol and cortisone were extracted into
dichloromethane, and dried extracts were analysed by radio-
immunoassay using Guildhay sheep anticortisol antiserum
(HPS 631-1G) and cortisol-3CMO-histamine-[125-I] as
tracer [28]. Urine cortisone was extracted into chloroform
and analysed by radioimmunoassay using rabbit anticorti-
sone antiserum (N-137) and 21-acetyl-cortisone-3CMO-
histamine-[125-I] as tracer [29]. Interassay CV% was less
than 12% for cortisol concentrations over 50nmol/l and less
than 10% for urine cortisone concentrations over 10 nmol/l.
Cortisol metabolite measurements
Urinary steroid profile analysis was carried out by high-
resolution gas chromatography of methyloxime-trimethyl-silyl ether (MO-TMS) derivatives as previously described
[30]. The intra- and interassay CVs were between 7.1%
and 21.1%, and 11.2% and 21.9%, respectively, for
different metabolites. Cortisol metabolites were calculated
as Ag/3-h period. Derived sums were as previously reported
[31]. TCM were determined from the sum of tetrahydro-
cortisone (THE), tetrahydrocortisol (THF), allo-THF
(5aTHF), a-Cortolone, h-Cortolone, a-Cortol, and h-Cortol.
11-Hydroxy-cortisol metabolites (11OH) were derived from
the sum of THF, 5aTHF, a-cortol, and [(h-Cortolone+
h-Cortol)0.5]. 11-Oxo-cortisol metabolites (11OXO) were
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Cortolone+h-Cortol)0.5]. 20-Hydroxy metabolites of corti-
sol were determined from the sum of a-Cortolone, h-
Cortolone, a-Cortol, and h-Cortol, and 20-oxo metabolites
of cortisol were determined from the sum of THE, THF, and
5aTHF. The ratios of 11OH/11OXO metabolites and THFs/
THE ((THF+5aTHF)/THE) were calculated as indices of total
net 11-h-HSD activity. The ratio 5a/5hTHF (5aTHF/THF)
was calculated as an index of 5a versus 5h reduction and
20OH/20OXOmetabolites as an index of net 20-HSD activity.
Circadian rhythm analysis
To determine the circadian rhythm parameters of each
variable, individual and population mean cosinor analysis
was performed using TSA-Seriel Cosinor software (Expert
Soft Technologie, Laboratoire d’Informatique BioMédicale,
France), for analysis of biological time series by least squares
estimation. Population-mean cosinor analysis is based on the
means of parameter estimates obtained from individuals in
the study sample to derive the following parameters: (1) the
goodness of fit of a cosinor curve fitted to the data; (2)
midline estimate statistic of rhythm (MESOR), defined as the
rhythm adjusted mean; (3) amplitude, defined as half the
extent of rhythmic change in a cycle approximated by a fitted
curve (difference between nadir and peak); and (4) acrop-
hase, defined as the time of peak in the cosinor curve fitted to
the data. The acrophase is expressed as a phase angle in
degrees; thus, the formula ((value in degrees/3608)24 h)
can be used to establish the time of peak.
Statistical analyses
Urinary free cortisol and cortisone values were calculated
as nmol/3 h, while urinary cortisol metabolites were
calculated as Ag/3 h. Group comparisons were made by the
independent t test (using SPSS for windows V 11) because
males and females did not show significant deviations from a
normal distribution. For comparison of hormone levels across
the entire period, we used a repeated measures analyses of
variance (ANOVA)with planned post hoc t tests on values forTable 2
Circadian rhythm parameters of urinary cortisol, cortisone, and their ratio in heal
Controls (n=20)
Urinary cortisol Urinary cortisone
Cortisol/
ratio
% Rhythm (goodness of fit) 77 78 58
Pb.0005 Pb.0005 P=.1
MESOR (nmol/3 h) 31 (23–37)TT 47 (36–52)** 0.67 (0.59







Values are expressed as means (95% confidence intervals). Acrophase is presente
T For controls vs. CFS: Pb.05.
TT For controls vs. CFS: Pb.0005.each of the 3-h blocks over 24 h to determine if there were any
differences in cortisol levels at a particular time of the day.Results
The demographic and clinical details of the CFS
participants are presented in Table 1. There was no difference
between the mean age and BMI of each group.
Urinary free cortisol and cortisone
The levels of urinary free cortisol and cortisone are shown
in Fig. 1A, B. Using ANOVA, levels of urinary free cortisol
and cortisone showed significant main effects of group
[ F(1,33)=27.6 and F(1,33)=30.2, respectively, both
Pb.0001] and time [Hotelling’s Trace=2.9, F(2,76)=22.8,
Pb.0001; 2.2, F(2,80)=16.8, Pb.0001, respectively], but no
difference in the group-by-time interaction [Hotelling’s
Trace=0.10, F(2,76)=1.2, P=.22; 0.18, F(2,80)=1.4, P=.27,
respectively]. Thus, cortisol and cortisone levels were
significantly lower in CFS across the period (main effect of
group), there was a diurnal fluctuation in cortisol and
cortisone levels (main effect of time), and the diurnal pattern
was not significantly different between CFS and controls
(group-by-time interaction). Post hoc t tests showed signifi-
cantly lower levels of cortisol and cortisone at all time points
except for 1800–2100 h. Mean differences (with 95%
confidence intervals in parentheses) between the patients
and controls for free cortisol were as follows (nmol/3 h):
(a) 0600–0900 h: 24.5 (6–43), Pb.01; (b) 0900–1200 h:
27 (9–46), Pb.001; (c) 1200–1500 h: 20 (2–39), Pb.05; and
(d) 1500–1800 h: 15 (3–31), Pb.05. The same values for
cortisone were (a) 0600–0900 h: 36 (11–62), Pb.001;
(b) 0900–1200 h: 35 (9–60), Pb.01; (c) 1200–1500 h:
25 (6–43), Pb.01; and (d) 1500–1800 h: 19 (0.4–37), Pb.05.
The ratio of urinary free cortisol to cortisone across the day
is shown in Fig. 1C. Using ANOVA, there was no significant
main effect of group [F(1,33)=0.67, P=.42], time [Hotel-
ling’s Trace=0.095, F(3,97)=0.7, P=.60], or group-by-time
interaction [Hotelling’s Trace=0.16, F(3,97)=1.2, P=.33].thy controls and patients with CFS over 15 h
Patients with CFS (n=15)
cortisone
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d as phase angle in degrees, where 3600=24 h.
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patients and controls.
Cosinor analysis-derived population-mean circadian
parameter estimates for controls and patients with CFS are
detailed in Table 2. Patients with CFS showed a significant
rhythm of cortisol (70%) and cortisone (71%, both Pb.0005),
similar to the patterns seen in controls. There was no
difference in the acrophase between the CFS and controls.
However, MESOR and the amplitude of both urinary cortisol
and urinary cortisone were significantly lower in the CFS
compared with the controls. The mean difference (95% CI)
for urinary free cortisol MESOR was 17 nmol/3 h (25 to 8,
Pb.0005) and 9 nmol/3 h for amplitude (18 to 2, Pb.05). The
values for urinary free cortisone showed a mean difference in
the MESOR of 25 nmol/3 h (35 to 15, Pb.0005) and a mean
difference in amplitude of 9 nmol/3 h (19 to 2, Pb.05). No
significant rhythm of the urinary free cortisol/urinary
cortisone ratio was noted for either CFS or controls (58%,
P=.1; 58%, P=.09, respectively).
Urinary cortisol metabolites
The levels of urinary cortisol metabolites and cortisol
metabolite ratios are shown in Fig. 2A–D. On ANOVA,
there was a significant main effect of time on TCM
[Hotelling’sTrace=2.15,F(2,67)=16.1,PV.0001] and a signi-Fig. 2. Mean values and standard errors of (A) urinary cortisol metabolites, (B) 11O
patients (n=15) and healthy controls (n=20) at a 3-h interval for 15 h.ficant group-by-time interaction [Hotelling’s Trace=0.37,
F(2,67)=2.8, P=.045], demonstrating that the diurnal pattern
of cortisol metabolites in CFS is significantly different than
that in controls, but no group difference [F(1,33)=2.4,
P=.13], confirming that patients and controls had similar
overall urinary cortisol metabolite levels. Post hoc t tests
showed that urinary cortisol metabolite excretion was not
significantly different between CFS and controls at any of
the individual time points.
The ratio 11OH/11OXO in CFS showed no effect of group
[F(1,33)=0.13, P=.7] or time [Hotelling’s Trace=0.17,
F(3,91)=1.3, P=.20] and no group-by-time interaction
[Hotelling’s Trace=0.32, F(3,91)=2.4, P=.67]. Findings were
similar for THFs/THE.
The ratios of 5a/5hTHF and 20OH/20OXO in CFS
showed significant effects of time [Hotelling’s Trace=0.44,
F(3,84)=3.0, P=.02; and 0.41, F(3,100)=3.0, P=.03, respec-
tively], confirming the presence of a diurnal change.
However, there was no group difference [F(1,33)=1.15,
P=.2, and F(1,33)=1.20, P=.3, respectively] or group-
by-time interaction [Hotelling’s Trace=0.13, F(3,84)=1.02,
P=.4, and 0.027 F(3,100)=0.2, P=.9, respectively]. Consid-
ering the differences in 5a/5hTHF and 20OH/20OXO ratios
at each 3-h period, post hoc t tests showed that these ratios
were not significantly different between CFS and controls at
any of the individual time points (Fig. 2C and D).H/11OXO ratio, (C) 5a/5h THF ratio, and (D) 20OH/20OXO ratio in CFS
Table 3
Comparison of circadian rhythm parameters of total urinary cortisol metabolites and their metabolite ratios in patients with CFS and controls over 15 h
Controls (n=20) Patients with CFS (n=15)
Urinary cortisol
metabolites 11-OH/11-Oxo 5F/5FTHF 20OH/20OXO
Urinary cortisol




74 45 69 60 72 51 66 60





















































Values are expressed as means (95% CI). Acrophase is presented as phase angle in degrees, where 3600=24 h.
Controls vs. CFS: The P values of all the above parameters were greater than .05, taken as nonsignificant, using independent t test.
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parameter estimates for controls and patients with CFS are
detailed in Table 3. Patients with CFS showed a significant
rhythm of total urinary cortisol metabolites (72%, Pb.0005).
The amplitude and MESOR were not different in the CFS
compared with the controls (mean difference=25, 95% CI:
193 to 143, P=.7; 11, 95% CI: 170 to 148, P=.8,
respectively), with no significant changes in the acrophase.
The ratio of 5a/5hTHF and 20OH/20OXO showed a
significant circadian rhythm in CFS (66% and 60%, both
Pb.05, respectively), whereas there was no significant
rhythm of 11OH/11OXO ratio in either CFS or controls
(51%, P=.1, and 45%, P=.2, respectively).Discussion
Diurnal levels of urinary cortisol
In this study, we found lower levels of urinary free cortisol
throughout the course of the day in patients with CFS, but
with unchanged diurnal rhythm. These findings are consistent
with and add weight to the previous literature showing
reduced urinary free cortisol in CFS [3,10–12]. Furthermore,
our findings have shown this reduction in urinary free cortisol
at nearly all times of the day, something not previously
reported; previous studies all used single 24-h collections.
However, two other studies in the literature found no change
in urinary cortisol in CFS [13,14]. Murphy [32] noted that all
studies of UFC in CFS had been obtained using radio-
immunoassays without chromatography, which gives values
considerably higher than those reported in studies that used
prior chromatography, and suggested that the higher levels in
normals than in CFS might thus be due to a higher cross-
reactivity of cortisol metabolites. However, we have found no
difference in cortisol metabolites in CFS that might account
for a changed level of cross reactivity (Jerjes et al.,
unpublished data). While the studies based on high-resolu-
tion chromatography by Schoneshofer et al. [33] might be
expected to give values least distorted by interference, valuesbased on GC-MS are higher and closer to those of radio-
immunoassays [32]; hence, doubt remains about the accuracy
of these alternative approaches.
Patient selection criteria may be another confounder
contributing to inconsistent findings in the literature. In the
study of Hamilos et al. [14], 2/7 patients hadmajor depression
and 1/7 panic disorder. In the study of Young et al. [13],
patients with major depression and anxiety were excluded,
but 10/22 with CFS had previous depressive disorder.
Furthermore, testing in both those two studies was not carried
out in a naturalistic setting, as the participants all came into a
laboratory for the duration of the sampling. There may have
been an additional effect of stress that might have obscured
any underlying changes in basal cortisol levels.
Notwithstanding these potential explanations, we have
previously commented on the lack of consensus of studies of
basal HPA axis function in CFS [34]. Some of the differences
can be ascribed to differences in the populations studied
(including psychiatric comorbidity, duration of illness,
symptom profile, and severity of illness) and quality of
methodology. However, approximately half of the best-
designed studies do show low cortisol levels. Our study adds
further to this literature by using a more frequent and
noninvasive sampling protocol over the course of 15 h in a
naturalistic setting and finding lowered levels of cortisol in
urine in CFS.
Diurnal levels of urinary cortisone
We found that the urinary cortisone profile in CFS shows a
diurnal rhythm similar to that of cortisol, with highest values
in the morning at between 0900 and 1200 h and a nadir in the
evening. The reduced urinary cortisone MESOR and reduced
cortisone values at individual time points parallels the
decreased urine cortisol in CFS patients compared with
controls. A similar covariance of serum cortisol and cortisone
has been seen in patients with major depression, although in
the direction of increased levels of both [35]. This is, to our
knowledge, the first study to demonstrate a reduced sponta-
neous urinary cortisone concentration in patients with CFS.
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To the best of our knowledge, the diurnal rhythm of
urinary cortisol metabolites has not been investigated to date
in patients with CFS.We found that, as with cortisol itself, the
cortisol metabolite rhythm in urine was not phase shifted. The
amplitude and MESOR of the cortisol metabolite rhythm
were not significantly different in CFS compared with
controls. These latter findings were consistent with the
overall unchanged daily mean levels of cortisol metabolites
as well as the unchanged values at most individual time points
over 15 h on ANOVA. Our study of 24-h excretion of cortisol
metabolites in CFS in a separate group of patients also
showed no differences comparedwith healthy controls (Jerjes
et al., unpublished data).
Cortisol to cortisone interconversion
In humans, cortisone derives mainly from the oxidation of
the 11-hydroxyl function of cortisol to the 11-keto form by
11-h-HSD Type 2. 11-HSD Type 2 is mainly located in
mineralcorticoid target tissues, principally kidney, colon
[36,37], and the parotid gland [38,39]. Inversely, the
conversion of cortisone to cortisol takes place mainly in
the liver [40], under the action of 11-h-HSD Type 1. The
ratios of urinary free cortisol/cortisone and 11OH/11OXO
represent an index of 11-h-HSD activity. Weber et al. [35]
reported no alteration in serum cortisol/cortisone in patients
with severe major depression. In contrast, Raven and Taylor
[41] reported an increased of 11OH/11OXO ratio, suggesting
an alteration of 11-h-HSD activity in depressed women,
although the phenomenon could not be demonstrated in
depressed men. Further support for this comes from a recent
study demonstrating an increase of ratio in both depressed
men and women [42]. The increase of net cortisol to
cortisone interconversion is coupled with enhancement of
cortisol metabolic clearance and vice versa [43].
To the best of our knowledge, the ratio of free urinary
cortisol/cortisone and their metabolites have not been pre-
viously measured in CFS patients. We found no significant
diurnal rhythm in the urinary free cortisol/cortisone and
11OH/ 11OXO ratios in either patients or controls. There
were no significant differences in the ratio at each time point
between patients and controls. This underscores the tight
relationship between cortisol and cortisone and points to an
unchanged activity of the 11-h-HSD enzymes. These data
parallel our observations of no change in the salivary cortisol/
cortisone ratio in the same CFS group [44].
Other pathways of cortisol metabolism
We also demonstrated significant diurnal rhythms of
5a/5h THF and 20OH/20OXO ratios in CFS, which were
not different from those of the controls. In contrast, an
increase of 5a/5h THF ratio was noted in patients with
major depression [45,46].Implications
We have thus found that urine free cortisol and free
cortisone are lower in CFS, but urinary excretion of cortisol
metabolites is unchanged and indices of cortisol metabolism
show no differences. This combination of findings cannot
be explained by an altered diurnal rhythm in CFS, but could
be explained by an enhanced cortisol metabolic clearance
rate. No direct measures of cortisol clearance have been
undertaken in CFS to date. An increase in metabolic
clearance rate of cortisol can result from changed cortisol
metabolism:We have proposed that a reduced 11OH/11OXO
ratio in patients with polycystic ovary was indicative of an
elevated cortisol oxidation, which resulted in the enhance-
ment of the cortisol metabolic clearance rate [47]. This study
provides no support for such changes in CFS, but because
urinary free cortisol represents only 2–3% of total cortisol
production, a relatively small increase in the rate of cortisol
metabolism could conceivably lead to a reduction in detect-
able free steroid without being reflected in our measures of
metabolites. Similarly, the possibility of lower free steroid
levels in CFS being due to lower cross-reaction in the assay
cannot be excluded. However, the metabolite analysis has
shown no differences that might suggest a candidate cross-
reactant. The methodology we used, based on immunoassay
of methylene chloride extracted material, has been ques-
tioned [32], but we are not convinced that any method can yet
be claimed to guarantee a btrueQ value. Further work needs to
explore the use of other measures to assess cortisol synthesis
in CFS, such as infusion of isotopically labelled cortisol to
measure production rate, with the ultimate aim of determining
the role of cortisol in the pathogenesis CFS.
The following limitations should be noted. Patient
selection criteria were rigorous; thus, our results may not be
representative of CFS patients as a whole. The consumption
of alcohol and caffeine was not recorded.We cannot therefore
exclude an effect of differences in this on our results, although
all participants were instructed to limit to their intake during
the collection period. We did not record menstrual cycle in
female participants because we have previously found no
changes of the studied steroid metabolites over the menstrual
cycle (NFT, unpublished observation) and no relationship of
menstrual cycle and cortisol circadian rhythm has been found
using saliva sampling [48]. Furthermore, a recent study found
no differences in plasma cortisol between follicular and luteal
phases in either CFS patients or healthy controls [49].
Conclusion
The main findings of this study are that we found further
evidence of reduced urinary cortisol levels in a new sample
of patients with CFS, selected to be free of the confounding
influence of medication and psychiatric comorbidity. We
have demonstrated that the reduction in urinary free cortisol
is present throughout the day, and we have also shown for
the first time that urinary cortisone has a similar circadian
W.K. Jerjes et al. / Journal of Psychosomatic Research 60 (2006) 145–153152variation to urinary cortisol, with reduced levels of cortisone
also present in CFS patients. We have also demonstrated in
CFS a significant diurnal rhythm of urinary cortisol
metabolites, which is not different from that of controls,
and with unchanged levels. Finally, we have demonstrated
similar ratios of urinary free cortisol/cortisone and 11OH/
11OXO, which remain almost constant throughout the day,
suggesting that the activity of 11-h-HSD 1 relative to
11-h-HSD 2 has not changed in CFS patients. Changes in
this metabolic pathway are not likely to underlie previous
findings of low urinary free cortisol levels in CFS.Acknowledgments
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